Item 8.01. Other Events.

On April 24, 2023, Orion Biotech Opportunities Corp. (the "Company") issued a press release announcing that as of the close of business on May 17, 2023, the publicly held Class A ordinary shares, par value $0.0001, will be deemed cancelled and will represent only the right to receive their pro-rata share in the Company's trust account, because the Company will not consummate an initial business combination within the time period required by its Amended and Restated Memorandum and Articles of Association.

The Company's sponsor has agreed to waive its redemption rights with respect to its outstanding Class B ordinary shares issued prior to the Company's initial public offering. There will be no redemption rights or liquidating distributions with respect to the Company's warrants, which will expire worthless.

The Company will file a Form 25 with the Commission in order to delist the Company's securities. The Company thereafter expects to file a Form 15 with the Commission to terminate the registration of the Company's securities under the Securities Exchange Act of 1934, as amended.

A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits.





Exhibit No.                                   Description
99.1            Press release, dated April 24, 2023
104           Cover Page Interactive Data File (embedded within the Inline XBRL document).




                                       1

© Edgar Online, source Glimpses